Treatment with Nuformix’s experimental therapy NXP002 reduced markers of fibrosis, or tissue scarring, in a laboratory model of…
Articles by Marisa Wexler, MS
Black patients with pulmonary fibrosis (PF) are diagnosed around a decade earlier than their white counterparts in the U.S.,…
Being exposed at work to medium or high levels of asbestos is associated with a near double risk of developing…
The U.S. Food and Drug Administration (FDA) has granted INS018_055 orphan drug designation for the treatment of idiopathic pulmonary fibrosis…
The Phase 3 REBUILD clinical trial testing INOpulse (inhaled nitric oxide) in people with pulmonary fibrosis (PF) has enrolled…
A new startup company called Isterian Biotech has launched with the goal of developing new therapies for fibrotic diseases. Isterian…
A Phase 2b clinical trial testing NP-120 (ifenprodil) as a treatment for chronic cough is expected to begin later this…
Treatment with an extract of scorpion venom eased lung scarring in a mouse model of pulmonary fibrosis (PF), a…
Pliant Therapeutics’ experimental oral anti-fibrotic therapy bexotegrast has received orphan drug designation from the European Medicines Agency (EMA) as…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ifenprodil, the active agent in NP-120, an…